As the ongoing trade war evolves, President Trump has signaled imminent major tariffs on pharmaceuticals, raising concerns about rising costs and potential drug shortages. Experts warn that these tariffs could exacerbate issues for consumers, with some suggesting that they might lead to soaring drug prices before any benefits materialize for U.S. manufacturing. Stocks of major pharmaceutical companies, including Novo Nordisk and AbbVie, have already seen declines in response to the tariff threats. Despite a recent 90-day pause in wider trade tensions, the pharmaceutical sector remains on high alert as Trump reiterates plans for new tariffs, leaving both investors and consumers uncertain about the future of drug pricing and availability.